What is Laboratorios Farmaceuticos Rovi EV-to-FCF?
Laboratorios Farmaceuticos RoviFRA:41L +0.87%93 EV-to-FCF is 25.80 as of Jul. 04, 2026, which is 7% below its 10-year median of 27.70. GuruFocus rates FRA:41L with a GF Score™ of 93/100 and a GF Value™ of €51.89 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 562 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 55.52% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's EV-to-FCF or its related term are showing as below:
FRA:41L'
s EV-to-FCF Range Over the Past 10 Years
Min: -456.95 Med: 27.7 Max: 408.96
Current: 25.8
During the past 13 years, the highest EV-to-FCF of Laboratorios Farmaceuticos Rovi was 408.96. The lowest was -456.95. And the median was 27.70.
FRA:41L's EV-to-FCF is ranked worse than 55.52% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.525
vs FRA:41L: 25.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Laboratorios Farmaceuticos Rovi's PE Ratio (TTM) for today is calculated as:
Laboratorios Farmaceuticos Rovi's share price for today is €57.90.
Laboratorios Farmaceuticos Rovi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.576.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Laboratorios Farmaceuticos Rovi EV-to-FCF Related Terms
Laboratorios Farmaceuticos Rovi EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's EV-to-FCF falls into.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,940.3 Mil.
Laboratorios Farmaceuticos Rovi's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €114.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (FRA:41L) has a EV-to-FCF of 25.80 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is near median its historical median of 27.70. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #312 out of 562 companies in the Drug Manufacturers industry, placing it in the top 55.5%.
Is Laboratorios Farmaceuticos Rovi's EV-to-FCF too high?
Laboratorios Farmaceuticos Rovi's current EV-to-FCF of 25.80 is near median its 10-year median of 27.70. The Drug Manufacturers industry median EV-to-FCF is 20.53. Laboratorios Farmaceuticos Rovi's value of 25.80 is 25.7% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #312 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #312 out of 562 companies for EV-to-FCF. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median EV-to-FCF is 20.53. Laboratorios Farmaceuticos Rovi's value of 25.80 is 25.7% above this benchmark. While the company's 10-year median is 27.70 vs. the industry median of 20.53, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current EV-to-FCF of 25.80 is 25.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current EV-to-FCF is 25.80, which is near median its own 10-year median of 27.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Modestly Overvalued. The stock's GF Value™ is €51.89, compared to a current price of €57.90 — trading 11.6% above its estimated fair value. The current EV-to-FCF is 25.80, which is near median its 10-year median of 27.70 and 25.7% above the Drug Manufacturers industry median of 20.53. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current EV-to-FCF is 25.80 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €57.90 is trading 11.6% above its estimated GF Value™ of €51.89.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for FRA:41L:
EV-to-FCF: 25.80 (near median its 10-year median of 27.70)
GF Value™: €51.89 vs. price of €57.90 (11.6% above fair value)
Industry Position: 25.7% above the Drug Manufacturers median (#312 of 562)
No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for FRA:41L
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:41L has been successfully added to your 
